Actavis PLC and Allergan Inc. are nearing a friendly deal that could swipe the Botox maker from hostile suitor Valeant Pharmaceuticals International Inc., according to people familiar with the matter. The boards of the two companies are expected to meet to review a cash-and-stock deal, the people said. An agreement could be announced as early as Monday, some of the people said, but timing could slip and one person said later in the week could be more likely
Nov 16 (Reuters) - Allergan Inc is near a deal to merge with Actavis Plc, with an agreement to be announced as soon as Monday, according to a person familiar with the matter. Actavis is likely to pay Allergan between $210 and $220 per share, according to the source.
